DE07776925T1 - Kristalline Form eines nach der Lagerung stabilen Atorvastatin-Calciums - Google Patents
Kristalline Form eines nach der Lagerung stabilen Atorvastatin-Calciums Download PDFInfo
- Publication number
- DE07776925T1 DE07776925T1 DE07776925T DE07776925T DE07776925T1 DE 07776925 T1 DE07776925 T1 DE 07776925T1 DE 07776925 T DE07776925 T DE 07776925T DE 07776925 T DE07776925 T DE 07776925T DE 07776925 T1 DE07776925 T1 DE 07776925T1
- Authority
- DE
- Germany
- Prior art keywords
- calcium
- crystalline form
- atorvastatin hemi
- storage
- crystalline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Kristalline
Form von Atorvastatin-Hemi-Calcium, gekennzeichnet durch ein Pulverröntgenbeugungsmuster
mit Peaks bei 6,9, 9,3, 9,6, 16,3, 17,1, 19,2, 20,0, 21,6, 22,4,
23,9, 24,7, 25,6 und 26,5 ± 0,2
Grad 2θ, die
gegen die Bildung von Atorvastatin-calciumepoxydihydroxy (AED) stabil
ist.
Claims (8)
- Kristalline Form von Atorvastatin-Hemi-Calcium, gekennzeichnet durch ein Pulverröntgenbeugungsmuster mit Peaks bei 6,9, 9,3, 9,6, 16,3, 17,1, 19,2, 20,0, 21,6, 22,4, 23,9, 24,7, 25,6 und 26,5 ± 0,2 Grad 2θ, die gegen die Bildung von Atorvastatin-calciumepoxydihydroxy (AED) stabil ist.
- Kristalline Form von Atorvastatin-Hemi-Calcium nach Anspruch 1, welche nach Lagerung bei einer Temperatur von etwa 40°C bei einer relativen Feuchte von etwa 75% für wenigstens etwa einen Monat weniger als etwa 0,01% (w/w) AED enthält.
- Kristalline Form von Atorvastatin-Hemi-Calcium nach Anspruch 1, welche nach Lagerung bei einer Temperatur von etwa 25°C bei einer relativen Feuchte von etwa 60% für wenigstens etwa 6 Monate weniger als etwa 0,01% (w/w) AED enthält.
- Kristalline Form von Atorvastatin-Hemi-Calcium nach einem der Ansprüche 1 bis 3, welche ein Isopropanolat oder ein Ethanolat ist.
- Pharmazeutische Zusammensetzung, welche das Atorvastatin-Hemi-Calcium nach einem der vorangegangenen Ansprüche umfaßt.
- Kristallines Atorvastatin-Hemi-Calcium nach einem der Ansprüche 1 bis 4 zur Verwendung in der Therapie.
- Kristallines Atorvastatin-Hemi-Calcium nach einem der Ansprüche 1 bis 4 zur Verwendung beim Reduzieren von Cholesterol oder LDL.
- Verwendung eines kristallinen Atorvastatin-Hemi-Calciums nach einem der Ansprüche 1 bis 4 für die Herstellung eines Medikaments zum Reduzieren von Cholesterol oder LDL.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20060431183 | 2006-05-09 | ||
US11/431,183 US20070265456A1 (en) | 2006-05-09 | 2006-05-09 | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
PCT/US2007/011236 WO2007133597A1 (en) | 2006-05-09 | 2007-05-08 | Crystalline form of atorvastatin calcium stable after storage |
Publications (2)
Publication Number | Publication Date |
---|---|
DE07776925T1 true DE07776925T1 (de) | 2008-07-03 |
DE07776925T8 DE07776925T8 (de) | 2009-04-30 |
Family
ID=38512661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE07776925T Active DE07776925T8 (de) | 2006-05-09 | 2007-05-08 | Kristalline Form eines nach der Lagerung stabilen Atorvastatin-Calciums |
Country Status (11)
Country | Link |
---|---|
US (1) | US20070265456A1 (de) |
EP (1) | EP2024331A1 (de) |
JP (2) | JP2009500429A (de) |
KR (1) | KR20080015510A (de) |
CN (1) | CN101437791A (de) |
BR (1) | BRPI0702876A2 (de) |
CA (1) | CA2649708A1 (de) |
DE (1) | DE07776925T8 (de) |
ES (1) | ES2312307T1 (de) |
IL (1) | IL194876A0 (de) |
WO (1) | WO2007133597A1 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3009423A3 (de) * | 2001-06-29 | 2016-12-28 | Warner-Lambert Company LLC | Kristalline formen des calciumsalzes (2:1) von [r-(r*,r*)]-2-(4-fluorphenyl)-beta, delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-(phenylamino)carbonyl]-1h-pyrrol-1-heptansäure (atorvastatin) |
BRPI0610344A2 (pt) | 2005-12-13 | 2016-11-29 | Teva Pharma | forma cristalizada do atorvastatin hemi-calcium, processo para sua preparação, produto famacêutico derivado e seu uso medicinal |
KR20120011249A (ko) | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
CN104945300B (zh) * | 2015-06-17 | 2017-05-10 | 北京嘉林药业股份有限公司 | 一种ⅰ型阿托伐他汀钙的纯化方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
ES2167587T3 (es) * | 1995-07-17 | 2002-05-16 | Warner Lambert Co | Forma cristalina de la sal hemicalcica del acido (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (atorvastatina). |
IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
CA2475864A1 (en) * | 2002-02-15 | 2003-08-28 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix |
CN100379723C (zh) * | 2002-02-19 | 2008-04-09 | 特瓦制药工业有限公司 | 阿托伐他汀半钙脱溶剂的方法和基本上不含有机溶剂的阿托伐他汀半钙 |
CN1997651B (zh) * | 2004-07-16 | 2012-06-06 | 力奇制药公司 | 阿托伐他汀钙的氧化降解产物 |
ES2262459T1 (es) * | 2004-07-22 | 2006-12-01 | Teva Pharmaceutical Industries Ltd | Nuevas formas cristalinas de atorvastatina semicalcica y procedimientos para su preparacion. |
DE05800195T1 (de) * | 2004-09-28 | 2006-12-28 | Teva Pharmaceutical Industries Ltd. | Verfahren zur Herstellung von Atorvastatin-Calcium, die im wesentlichen frei von Verunreinigungen sind |
-
2006
- 2006-05-09 US US11/431,183 patent/US20070265456A1/en not_active Abandoned
-
2007
- 2007-05-08 WO PCT/US2007/011236 patent/WO2007133597A1/en active Application Filing
- 2007-05-08 EP EP07776925A patent/EP2024331A1/de not_active Withdrawn
- 2007-05-08 CA CA002649708A patent/CA2649708A1/en not_active Abandoned
- 2007-05-08 CN CNA2007800164419A patent/CN101437791A/zh active Pending
- 2007-05-08 KR KR1020087000648A patent/KR20080015510A/ko not_active Application Discontinuation
- 2007-05-08 BR BRPI0702876-8A patent/BRPI0702876A2/pt not_active IP Right Cessation
- 2007-05-08 DE DE07776925T patent/DE07776925T8/de active Active
- 2007-05-08 JP JP2008520455A patent/JP2009500429A/ja active Pending
- 2007-05-08 ES ES07776925T patent/ES2312307T1/es active Pending
- 2007-05-09 JP JP2007124711A patent/JP2007302665A/ja active Pending
-
2008
- 2008-10-23 IL IL194876A patent/IL194876A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2649708A1 (en) | 2007-11-22 |
KR20080015510A (ko) | 2008-02-19 |
US20070265456A1 (en) | 2007-11-15 |
ES2312307T1 (es) | 2009-03-01 |
CN101437791A (zh) | 2009-05-20 |
DE07776925T8 (de) | 2009-04-30 |
BRPI0702876A2 (pt) | 2011-03-15 |
JP2007302665A (ja) | 2007-11-22 |
WO2007133597A9 (en) | 2008-01-24 |
JP2009500429A (ja) | 2009-01-08 |
WO2007133597A1 (en) | 2007-11-22 |
IL194876A0 (en) | 2009-08-03 |
EP2024331A1 (de) | 2009-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE102004015723A1 (de) | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel | |
EP1886701A3 (de) | Markerkomposit für medizinische Implantate | |
DE07776925T1 (de) | Kristalline Form eines nach der Lagerung stabilen Atorvastatin-Calciums | |
EP2251338A3 (de) | Organische Verbindungen | |
DE13156663T1 (de) | NRF2-Screening-Assays sowie entsprechende Verfahren und Zusammensetzungen | |
DE04010435T1 (de) | Zolpidem Hemitartrat Solvat | |
EP1784388B8 (de) | Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen | |
NZ599889A (en) | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | |
WO2006114415A2 (de) | Physiologisch verträgliche salze von 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester | |
CA2649022A1 (en) | Cocrystal of c-glycoside derivative and l-proline | |
BR0309167A (pt) | Composto, processo para a produção de um composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afetado por uma condição patológica ou doença e produto de combinação | |
DE20220238U1 (de) | Glutaminyl basierte DPIV Inhibitoren | |
WO2005106492A3 (en) | Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 3 (ccr3) | |
DE14721256T1 (de) | Pharmazeutische zusammensetzungen mit kristallinem macitentan | |
DE502006004182D1 (de) | Substituierte 5,6,7,8-tetrahydro-imidazoä1 ,2-aüpyridin-2-ylamin-verbindungen und deren verwendung zur herstellung von arzneimitteln | |
RU2492163C9 (ru) | Соединения коричной кислоты (варианты), промежуточные соединения для их получения, фармацевтическая композиция на их основе, способ ингибирования гистоновой деацетилазы, способ лечения диабета, способ лечения опухоли или заболевания, связанного с пролиферацией клеток, способ усиления роста аксонов и способ лечения нейродегенеративных заболеваний и спинной мышечной атрофии | |
EP1738781A3 (de) | Verwendung von Propolis als Beschichtungmaterial für medizinische Implantate | |
EP1803777A3 (de) | Vernetzbare Massen auf der Basis von Organosiliciumverbindungen | |
DE102005060377A1 (de) | Pharmazeutische Zusammensetzung enthaltend Donepezilhydrochlorid, Tablette hieraus und Verfahren zu deren Herstellung | |
DE346013C (de) | Harte, in der Form unveraenderliche, unzerbrechliche und leicht bearbeitbare Gegenstaende, welche gegen X-Strahlen und radioaktive Strahlen undurchlaessig sind | |
CN1899046A (zh) | 抗菌密胺材料及其制备方法和在餐具中的应用 | |
WO2005106471A3 (en) | Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4) | |
EP1844764A3 (de) | Zusammensetzung zur Verwendung als Laxativum | |
EP2399648A3 (de) | Kosmetische Zusammensetzung und deren Verwendung | |
EP2336103A3 (de) | HCL-Polymorphe von 3-[2-(Dimethylamino)methyl-(cyclohex-1-yl)]phenol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8596 | Reprint of erroneous front page |